We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00746499
Recruitment Status : Completed
First Posted : September 4, 2008
Last Update Posted : October 15, 2012
Information provided by (Responsible Party):

September 3, 2008
September 4, 2008
October 15, 2012
September 2008
November 2008   (Final data collection date for primary outcome measure)
Drug levels in CVF and blood plasma [ Time Frame: Day 1-9 ]
Same as current
Complete list of historical versions of study NCT00746499 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
A Phase 1, Open-Label Study, Investigating First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Uninfected Women
Healthy subjects will take study drug by mouth twice a day for 7 consecutive days, blood and cervicovaginal samples will be taken most mornings around the AM dose. Two visits, ~14 hrs in length will be required on Day 1 and 7. The purpose of this study is to measure how much raltegravir is found in the genital tract after taking it orally.
This study is looking at blood and cervicovaginal fluid (CVF) samples of healthy volunteers taking raltegravir. The purpose of this study is to measure the extent that raltegravir penetrates into other body compartments, such as the genital tract. Subjects will take the study drug for 7 days, a total of 10 visits to the research center will be required. A screening visit will occur on no more than 28 days On Days 1 and 7 the subject will stay in the research center for approximately 12 hours for scheduled blood and CVF sampling. Days 3-6 and 8-9 will involve a short visit to the research center for one pre-dose blood and CVF sample before the morning dose. A follow up visit will occur about 7-10 days after last dose.
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Drug: Raltegravir
400mg raltegravir BID x 7 days
Other Name: Isentress
Experimental: 1
No control group, only one active arm with subjects taking Raltegravir.
Intervention: Drug: Raltegravir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2008
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy pre-menopausal female subjects
  • Between the ages of 18 and 49 years
  • With an intact uterus and cervix

(Healthy is defined as no irregular menstrual cycles or clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).

Exclusion Criteria:

  • Negative serum pregnancy test at screening and should be using at least one method of contraception
  • Body Mass Index (BMI) of approximately 18 to 30 kg/m^2
  • And a total body weight > 50 kg (110 lbs)
Sexes Eligible for Study: Female
18 Years to 49 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
IRB #08-0984
Not Provided
Not Provided
University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
Not Provided
Principal Investigator: Angela DM Kashuba, PharmD University of North Carolina
University of North Carolina, Chapel Hill
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP